

1P-298-T025

Monoclonal Antibody to CD105 Phycoerythrin (PE) conjugated (25 tests)

Clone: MEM-226

Isotype: Mouse IgG2a

Specificity: The antibody MEM-226 reacts with CD105 (Endoglin), a 90 kDa type I

homodimerizing membrane glycoprotein expressed on vascular endothelial cells (small and large vessels), activated monocytes and tissue macrophages, stromal cells of certain tissues including bone marrow, pre-B lymphocytes in fetal marrow and erythroid precursors in fetal and adult bone marrow; it is also present on

syncytiotrophoblast on placenta throughout pregnancy.

Regulatory Status: RUO

Immunogen: Recombinant Vaccinia virus containing the human CD105 cDNA.

Species Reactivity: Human, Rat

Preparation: The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum

conditions. The conjugate is purified by size-exclusion chromatography and

adjusted for direct use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

Usage: The reagent is designed for Flow Cytometry analysis of human blood cells using

20 μl reagent / 100 μl of whole blood or 10° cells in a suspension.

The content of a vial (0.5 ml) is sufficient for 25 tests.

Expiration: See vial label

Lot Number: See vial label

Background: CD105 (Endoglin) is a homodimeric transmembrane glycoprotein serving in

presence of TGFbetaR-2 as a receptor for TGFbeta-1 and TGFbeta-3. CD105 is highly expressed on endothelial cells and promotes angiogenesis during wound healing, infarcts and in a wide range of tumours and its gene expression is stimulated by hypoxia. CD105 prevents apoptosis in hypoxic endothelial cells and also antagonises the inhibitory effects of TGFbeta-1 on vascular endothelial cell growth and migration. Normal cellular levels of CD105 are required for formation of

new blood vessels.



PRODUCT DATA SHEET

References:

*Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA: Hypoxic induction of endoglin via mitogen-activated protein kinases in mouse brain microvascular endothelial cells. Stroke. 2003 Oct;34(10):2483-8.

*Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C, Kumar S: CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci. 2003 Jul 1;116(Pt 13):2677-85.

*Guo B, Slevin M, Li C, Parameshwar S, Liu D, Kumar P, Bernabeu C, Kumar S: CD105 inhibits transforming growth factor-beta-Smad3 signalling. Anticancer Res. 2004 May-Jun;24(3a):1337-45.

*Warrington K, Hillarby MC, Li C, Letarte M, Kumar S: Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells. Anticancer Res. 2005 May-Jun;25(3B):1851-64.

*Piao M, Tokunaga O: Significant expression of endoglin (CD105), TGFbeta-1 and TGFbeta R-2 in the atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb. 2006 Apr;13(2):82-9.

*Schmidt D, Achermann J, Ödermatt B, Breymann C, Mol A, Genoni M, Zund G, Hoerstrup SP: Prenatally fabricated autologous human living heart valves based on amniotic fluid derived progenitor cells as single cell source. Circulation. 2007 Sep 11;116(11 Suppl):164-70.

*Asumda FZ, Chase PB: Age-related changes in rat bone-marrow mesenchymal stem cell plasticity. BMC Cell Biol. 2011 Oct 12;12:44.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.